Clinical Activity of BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label Study

被引：38

作者：

Bal, Susan ^{[1
]}

Kocoglu, M. Hakan ^{[2
]}

Nadeem, Omar ^{[3
]}

Htut, Myo ^{[4
]}

Gregory, Tara ^{[5
]}

Anderson, Larry D., Jr. ^{[6
]}

Costa, Luciano J. ^{[1
]}

Buchholz, Tonia J. ^{[7
]}

Ziyad, Safiyyah ^{[7
]}

Li, Meng ^{[7
]}

Chen, Yanping ^{[7
]}

Kaeding, Allison J. ^{[7
]}

Burgess, Michael R. ^{[7
]}

Hege, Kristen ^{[7
]}

Berdeja, Jesus ^{[8
]}

机构：

[1] Univ Alabama Birmingham, Birmingham, AL USA

[2] Univ Maryland, Baltimore, MD 21201 USA

[3] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[4] City Hope Comprehens Canc Ctr, Duarte, CA USA

[5] Sarah Cannon Canc Network, Colorado Blood Canc Inst, Denver, CO USA

[6] UT Southwestern Med Ctr, Simmons Comprehens Canc Ctr, Cellular Therapy & Hematol Malignancies Program, Dallas, TX USA

[7] Bristol Myers Squibb, Princeton, NJ USA

[8] Sarah Cannon Res Inst, Nashville, TN USA

来源：

关键词：

D O I：

10.1182/blood-2022-162395

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3